News releases
Presentations
Finance
Share information
Event calendar
About us
R&D pipeline
Mailing list
IR Contact

 

 

 
 

NeuroSearch

 

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the Nasdaq OMX Copenhagen A/S.

 

The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders.  

 

Click here to read more about NeuroSearch
 

NeuroSearch announces positive top-line results from Phase III Huntexil® study in Huntington's disease (the MermaiHD study)

Copenhagen, 3 February 2010

 

  • Huntexil® significantly improves motor functions in Huntington patients
  • Positive effects observed on both voluntary and involuntary motor symptoms
  • Huntexil® was very well tolerated with an adverse event profile similar to placebo

     

Please click here to access audiocast

 

 

Neurosearch stock ticker
 

News releases

 

NeuroSearch announces positive top-line results from Phase III Huntexil® study in Huntington's disease (the MermaiHD study)
03 February 2010 - Announcement
NeuroSearch A/S announces end of stabilisation period in connection with the rights issue completed November 2009
14 December 2009 - Announcement
NeuroSearch A/S’ share capital and voting rights
30 November 2009 - Announcement
 

Events

 

08 February 2010
10 March 2010
18 March 2010
23 March 2010
24 March 2010
28 April 2010
15 May 2010
 

Huntexil® in Huntington’s disease

 

 


Presentations
 

 

 

01 December 2009
Company presentation
16 November 2009
Q3 Report 2009 - Teleconference
NeuroSearch A/S - Pederstrupvej 93 - 2750 Ballerup - Denmark - Tel.: +45 4460 8000 - Fax: +45 4460 8080 - CVR No.: DK-1254 6106
NeuroSearch Sweden AB - Arvid Wallgrens Backe 20 - 413 46 Gothenburg - Sweden - Tel.: +46 (0) 31 772 0600 - Fax: +46 (0) 31 772 0601 - CVR No.: 556552-5176
 copyright®2010 Legal disclaimer - ns@neurosearch.dk